A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant. The average time from investigational new drug (IND) filing to market was 6.7 years for 11 mABs approved between 1994 and 2003 but shot up to 8.3 years for 12 mAbs approved between 2004 and March 9, 2011, according to Deloitte Recap LLC’s analysis, Therapeutic Monoclonal Antibodies – Insights, Strategies and Data.

Dacryocystorhinostomy (DCR) is a procedure performed for the treatment of tearing (epiphora) due to blockage of the nasolacrimal duct. Tears originate in the lacrimal gland, located at the upper outer margin of the eye. As tears cross the eye with each blink, they are directed into small openings in the eyelids called puncta. From this point, tears travel through a pathway known as the canalicular system into the lacrimal sac. The lacrimal sac is located between the eye and the nose, and funnels tears into the nasal cavity through the nasolacrimal duct (Figure 1). As this is quite a long path for tears to travel, there can be many causes of excessive tearing. Blockage of the nasolacrimal duct is one common cause, and can be treated by creating a direct opening from the lacrimal sac into the nasal cavity in a procedure known as DCR. The evaluation and management of tearing may involve both an ophthalmologist and an otolaryngologist.

Neonatal resuscitation skills are essential for all health care providers who are involved in the delivery of newborns. The transition from fetus to newborn requires intervention by a skilled individual or team in approximately 10% of all deliveries. This figure is concerning because 81% of all babies in the United States are born in nonteaching, nonaffiliated level I or II hospitals. In such hospitals, the volume of delivery service may not be perceived as sufficient economic justification for the continuous in-hospital presence of personnel with high-risk delivery room experience, as recommended by the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists (ACOG). [1] Perinatal asphyxia and extreme prematurity are the 2 complications of pregnancy that most frequently necessitate complex resuscitation by skilled personnel. However, only 60% of asphyxiated newborns can be predicted ante partum. The remaining newborns are not identified until the time of birth. Additionally, approximately 80% of low-birth-weight infants require resuscitation and stabilization at delivery. Nearly one half of newborn deaths (many of which involve extremely premature infants) occur during the first 24 hours after birth. Many of these early deaths also have a component of asphyxia or respiratory depression as an etiology. For the surviving infants, effective management of asphyxia in the first few minutes of life may influence long-term outcome. Even though prenatal care can identify many potential fetal difficulties ante partum, allowing maternal transfer to the referral center for care, many women who experience preterm labor are not identified prospectively and therefore are not appropriately transferred to a tertiary perinatal center. Consequently, many deliveries of extremely premature infants occur in smaller hospitals. For this reason, all personnel involved in delivery room care of the newborn should be trained adequately in all aspects of neonatal resuscitation. Additionally, equipment that is appropriately sized to resuscitate infants of all gestational ages should be available in all delivering institutions, even if the institution does not care for preterm or intensive care infants. Along with the necessary skills, the practitioner should approach any resuscitation with a good comprehension of transitional physiology and adaptation, as well as an understanding of the infant's response to resuscitation. Resuscitation involves much more than possessing an ordered list of technical skills and having a resuscitation team; it requires excellent assessment skills and a grounded understanding of physiology.

The gradual curves of the human spine allow the body to absorb many shocks and stresses in daily life. It’s a delicate balance, though, and if part of the spine curves too much, pain and limited mobility may result.

There are 3 major parts of the respiratory system: the airway, the lungs, and the muscles of respiration. The airway, which includes the nose, mouth, pharynx, larynx, trachea, bronchi, and bronchioles, carries air between the lungs and the body's exterior.

CD4 T-cells (a type of white blood cell) are important to your body's defence against infections. This animation describes how your immune system is weakened by the HIV virus, which targets CD4 T-cells and leads to their gradual decline in number. Low to very low levels of CD4 cells put you at risk for 'opportunistic infections' that take advantage of the body's weakened immune system.

Herpes simplex encephalitis is characterized by acute-onset (<1 week) fever, headaches, seizures, altered mental status, and focal neurologic findings such as hemiparesis or cranial nerve deficits. This patient's weakness/fatigue for >1 week, heart murmur, history of drug abuse, and absence of focal neurologic deficits make endocarditis with mycotic aneurysm more likely than herpes encephalitis

-Almost all the cases of occupational transmission of HIV have been due to transmission via exposure to blood and certain body fluids. The body fluids wherein standard precautions have been recommended include semen, vaginal secretions, and any other body fluid containing visible blood. Other standard precautions, according to the Center for Disease Control and Prevention (CDC), also apply to cerebrospinal, peritoneal, pleural, pericardia!, synovial fluid, or any other tissue, even though the epidemiologic data regarding the risk of HIV transmission from these fluids is insufficient. Standard precautions do not apply to urine, sweat, tears, sputum, vomitus, and nasal secretions or feces, as long as there is no gross visible blood. The occupational transmission of HIV has never been documented from the above sources.

Candida Albicans is more than just yeast- for most people, it's already mutated into a more aggressive fungal form that eats holes through the intestinal tract causing many of todays health problems like food allergies, autoimmune disorders, Crohn's disease, IBS, low energy and many more aggressive diseases. People need to know what it is and what to do about it.

Deep Vein Thrombosis Treatment With Trellis Procedure

Eyelid surgery, or blepharoplasty, is a surgical procedure to improve the appearance of the eyelids. Surgery can be performed on either the upper and lower lids, or both. Whether you want to improve your appearance or are experiencing functional problems with your eyelids, eyelid surgery can rejuvenate the area surrounding your eyes.

Miracle baby's heart beats outside her chest

How do you know if you have an STD? There’s only one way — you have to get tested. How do they test for STDs? Here’s the good news: STD testing is usually quick and painless. Get answers to all your questions about how to get tested for STDs.

32 weeks pregnant, your baby has now nails on the toes and fingers. Watch this video to get detailed information of baby's development during this 33 week of pregnancy,

Classical PKU is an autosomal recessive disorder, caused by mutations in both alleles of the gene for phenylalanine hydroxylase (PAH), found on chromosome 12. In the body, phenylalanine hydroxylase converts the amino acid phenylalanine to tyrosine, another amino acid.

LSD is one of the most potent, mood-changing chemicals. It is manufactured from lysergic acid, which is found in the ergot fungus that grows on rye and other grains. It is produced in crystal form in illegal laboratories, mainly in the United States. These crystals are converted to a liquid for distribution. It is odorless, colorless, and has a slightly bitter taste.

Syringomyelia (sih-ring-go-my-E-lee-uh) is the development of a fluid-filled cyst (syrinx) within your spinal cord. Over time, the cyst may enlarge, damaging your spinal cord and causing pain, weakness and stiffness, among other symptoms. Syringomyelia has several possible causes, though the majority of cases are associated with a condition in which brain tissue protrudes into your spinal canal (Chiari malformation). Other causes of syringomyelia include spinal cord tumors, spinal cord injuries and damage caused by inflammation around your spinal cord. If syringomyelia isn't causing any problems, monitoring the condition may be all that's necessary. But if you're bothered by symptoms, you may need surgery.

What combines research opportunities, intellectual challenge, and international collaboration in the study of a disease which affects many organs of the body and all sectors of society? And demands that specialists from many different backgrounds work together to crack sometimes intractable problems? It is, of course, oncology. As a career choice, it's demanding; it takes passion coupled with a willingness to put in the hours and to learn how to discuss death honestly and sensitively. But for the right person, it can be immensely rewarding.

Decompression is a surgical procedure that is performed to alleviate pain caused by pinched nerves (neural impingement). During a lumbar decompression back surgery, a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment. There are two common types of spine surgery decompression procedures: Microdiscectomy Lumbar Microdiscectomy Microdiscectomy Surgery Video A microdiscectomy (a microdecompression) is typically performed for pain from a lumbar herniated disc. The surgery is considered reliable for leg pain caused by the herniated disc, most commonly called sciatica by patients, and most commonly referred to by medical practitioners as a radiculopathy. Read more about Microdiscectomy Surgery

The pathobiology of MM is complex and the root underlying cause of myeloma is the multistep genetic changes in the postgerminal center B cell. In addition, the bone marrow microenvironment plays a crucial role.[2] The interaction between myeloma cells and the microenvironment is mediated through adhesive interactions via cell-surface receptors, paracrine loops involving several cytokines, such as IL-6, VEGF and IL-10, and suppression of cell-mediated immunity.[2–4] IMiDs modulate many of these interactions leading to decreased myeloma cell growth and survival. Thalidomide was the first IMiD introduced to treat MM. It was initially synthesized in Germany in the late 1950s to treat insomnia and morning sickness. It was withdrawn from the market in 1961 because of its teratogenic effects. Its immunomodulatory properties were realized when it was observed to improve erythema nodosum leprosum, a painful immunologic reaction of leprosy, leading to its approval by the FDA in 1998 with tight prescribing and marketing regulations. Subsequent research showed the diverse mechanism of action of thalidomide including its immunomodulatory effect by inhibition of de novo IgM antibody synthesis,[5] modulation of the T-cell subset by increasing the T-helper cells, inhibitory effects on the TNF-α and antiangiogenic activity leading to its use in MM. Significantly higher response rates in combination with dexamethasone led to its approval in the treatment of newly diagnosed MM in 2006. Lenalidomide, a second-generation IMiD, was developed from the structural backbone of the thalidomide molecule by the addition of an amino group (NH2-) at position 4 of the phthaloyl ring and removal of the carbonyl group (C = O) of the 4-amino-substituted phthaloyl ring (Table 1).[6] In addition to immunomodulatory effects, other mechanisms of action have been described such as direct cytotoxicity via induction of apoptosis, inhibition of cell adhesion molecules and inhibition of growth signals that promote bone marrow angiogenesis